Kuhn J M, Gancel A, Weinstein A, Courtois H, Schrub J C, Tadie M, Wolf L M
Presse Med. 1985 Mar 2;14(9):525-8.
Forty-two patients with prolactin-secreting pituitary adenoma (prolactinoma) demonstrated by a radiologically abnormal sella turcica and hyperprolactinaemia were treated with bromocriptine. Baseline serum prolactin levels, which before treatment correlated with the size of the adenoma, returned to normal under bromocriptine in 30 out of 36 cases; in 6 female patients, however, they were lowered but remained moderately high. The dose of bromocriptine and the time required for normalization of prolactinaemia correlated with the size of the tumour. In 11 patients with macroadenoma bromocriptine dosage and prolactinaemia were inversely correlated; in 8 of these the adenoma was reduced in size. In 12 cases where the long-term treatment was interrupted, prolactinaemia rose again, suggesting that the medical treatment alone has no lasting curative effect.
42例经放射学检查显示蝶鞍异常且伴有高泌乳素血症的泌乳素分泌型垂体腺瘤(泌乳素瘤)患者接受了溴隐亭治疗。治疗前的基线血清泌乳素水平与腺瘤大小相关,36例患者中有30例在溴隐亭治疗下恢复正常;然而,6例女性患者的泌乳素水平虽有所降低但仍处于中度偏高。溴隐亭的剂量以及泌乳素血症恢复正常所需的时间与肿瘤大小相关。11例大腺瘤患者中,溴隐亭剂量与泌乳素血症呈负相关;其中8例患者的腺瘤体积缩小。12例中断长期治疗的患者,泌乳素血症再次升高,这表明单纯药物治疗没有持久的治愈效果。